clinical trial · NCT07352969
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
Innovent Biologics (Suzhou) Co. Ltd.·phase2·not yet recruiting·n = 352
HypertensionIBI3016Placebo
brief summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
started
Feb 6, 2026
primary completion
Mar 27, 2029
completion
Mar 27, 2029
last updated
Jan 20, 2026
detailed description
Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, 24 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of IBI3016 in Mild to Moderate Hypertensive Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol